ANIP (ANI Pharmaceuticals) Other Income (Expense) : $-6.8 Mil (TTM As of Dec. 2024)

View and export this data going back to 1999. Start your Free Trial

What is ANI Pharmaceuticals Other Income (Expense)?

ANI Pharmaceuticals's other income expense for the ANI Pharmaceuticals's pretax income for the three months ended in Dec. 2024 was $-9.1 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-6.8 Mil.

ANI Pharmaceuticals Other Income (Expense) Historical Data

The historical data trend for ANI Pharmaceuticals's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANI Pharmaceuticals Other Income (Expense) Chart

ANI Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Income (Expense)

Get a 7-Day Free Trial

-0.94

-15.97

-8.88

-2.72

-6.83

ANI Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Income (Expense)	Get a 7-Day Free Trial															-2.02	14.88	-3.16	-9.47	-9.08

ANI Pharmaceuticals Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.8 Mil.

ANI Pharmaceuticals (NAS:ANIP) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

ANI Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (NAS:ANIP) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

210 Main Street West, Baudette, MN, USA, 56623

Website

https://www.anipharmaceuticals.com

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Executives

Krista Davis	officer: SVP, CHIEF HR OFFICER	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Meredith Cook	officer: SR. VP, GENERAL COUNSEL & SEC.	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Ori Gutwerg	officer: SVP, GENERICS	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Stephen P. Carey	officer: Vice President and CFO	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Nikhil Lalwani	director, officer: PRESIDENT & CEO	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Christopher Mutz	officer: HEAD OF RARE DISEASE	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Muthusamy Shanmugam	director, officer: HEAD OF R&D, COO-NOVITIUM OPS	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Chad Gassert	officer: SVP - CORP. DEV. & STRATEGY	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Renee P Tannenbaum	director	9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
James G. Marken	officer: Vice President, Operations	210 MAIN STREET WEST, C/O BIOSANTE PHARMACEUTICALS, INC., BAUDETTE MN 56623
Antonio R Pera	director	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Matthew J Leonard	director	7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Meridian Venture Partners Ii Lp	10 percent owner
Jeanne Thoma	director	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh	director	14282 FRANKLIN AVE., TUSTIN CA 92780